WuXi Healthcare Invests In US Genomics Testmaker 23andMe

WuXi Healthcare Ventures, the investment arm of WuXi PharmaTech, participated in the $115 million E financing of California’s 23andMe. 23andMe offers a $199 direct-to-consumer saliva DNA test. According to one report, the test is a loss leader for the company, which is more interested in developing a genomics database than selling tests. About 80% of 23andMe’s customers -- about 100 million people -- allow the company to include their DNA reports (anonymously) in a genomic database. As WuXi ramps up its genomics services, the DNA database have sparked its interest in 23andMe. -

Help employers find you! Check out all the jobs and post your resume.